To engineer T h determinants (THd) to prime help for humoral or cytotoxic T cell responses, we modi®ed ovalbumin [OVA 323±337 ] and myoglobin [MYO 106±118 ] eliciting T h 1 and T h 0 cytokine pro®les respectively. Residues along the sequence of both THd were replaced with amino acids representative of different families. Replacements at positions P±1 and P5 pointing to the TCR in both THd afforded higher levels of IFN-g and IL-4 production. Peptides eliciting different proportions of IFN-g and IL-4 were co-immunized with a peptide hapten or a T cytotoxic determinant (TCd) respectively. OVA 323±337 -and MYO 106±118 -derived peptides afforded the best THd for the induction of cytotoxic T lymphocyte (CTL) and anti-hapten antibodies respectively. IFN-g and IL-4, primed by MYO 106±118 -derived peptides, correlated signi®cantly with antibody production against the hapten (P < 0.05 for IFN-g and P < 0.05 for IL-4). Interestingly, two peptides derived from OVA 323±337 , 323G and 327G, which induced the clearest T h 2 cytokine pro®les, were not the most ef®cient to prime cell help for the induction of anti-hapten antibodies. For CTL induction, OVA 323±337 -derived peptides, inducing a T h 1-like pro®le, required a lower dose (5 nmol) than T h 0 peptides (50 nmol). The dose of 50 nmol was detrimental for T h 1-like peptides. Interestingly, IFN-g primed by the THd correlated signi®cantly with that induced by the TCd (P < 0.01).
Introduction
T h lymphocytes (HTL) play a central role in the induction of antibodies (1) as well as cytotoxic T lymphocytes (CTL) (2, 3) . HTL are usually classi®ed according to the cytokine pattern they induce: T h 1 (IFN-g, tumor necrosis factor-b and IL-2), T h 2 (IL-4, IL-5, IL-6 and IL-13) and T h 0 (a mixture of cytokines from T h 1 and T h 2) (4,5). It has been described that a T h 1 cytokine pro®le is associated with CTL responses, whereas a T h 2 pro®le is associated with humoral (antibody) responses (2,6±8). HTL liberate cytokines following the recognition by the TCR of the complex between the peptide and the MHC class II molecules (MHC-II) presented at the surface of antigen-presenting cells (APC). Peptides presented by MHC-II are referred to as T h determinants (THd). Several factors such as dose of antigen (9±11), co-stimulatory molecules on APC (12±15), cytokine environment (16) and nature of the pathogen (17, 18) may have a profound effect on T cell differentiation to produce T h 1 or T h 2 cytokine pro®les. Other factors that affect this differentiation are the strength of interaction between the THd and the MHC-II (19±21), and the strength of recognition of the THd±MHC-II complex by the TCR (22±24). Based on this knowledge, several groups have carried out modi®cations in the sequence of THd in order to modify their interaction with either the MHC-II (19, 21) or the TCR (22±24) and reported that strong interactions favor T h 1 cytokine pro®les. We speculated that systematic replacement of amino acids along the sequence of two well-characterized peptides [both recognized by I-A d class II molecules (25, 26) ] by amino acids representative of different families might offer an insight on how changes in the interaction between peptide, MHC-II and TCR of HTL would alter the pattern of cytokines following the recognition of the peptide±MHC-II complex by the TCR. Thus, we selected K/E, M/Y and G/A as residues representative of hydrophilic (positively and negatively charged), hydrophobic (aliphatic and aromatic) and small residues respectively.
The crystal structure of the complex between the I-A d class II molecule and the THd OVA 323±337 , which encompasses residues 323±337 from ovalbumin (27) , has identi®ed those residues from OVA 323±337 that point towards the cleft of the I-A d molecule and those pointing to the TCR of the HTL (28) . By analogy to this structure, the same group assigned the relative orientation of amino acid residues from another THd, MYO 106±118 , which encompasses amino acids 106±118 from sperm whale myoglobin (29) . The knowledge of these two structures offered us the possibility of assigning the effect of amino acid replacements as mainly due to peptide±MHC-II or to peptide±TCR interactions. Moreover, since OVA 323±337 and MYO 106±118 induce T h 1 and T h 0 cytokine pro®les, and are able to prime T cell help for CTL and antibody induction respectively (30,31), we thought that both peptides might be good leading compounds to engineer different types of THd for the induction of humoral and CTL immune responses.
As shown by our group, antibodies against a nonimmunogenic B cell epitope can be elicited by co-immunization of this epitope and a THd (31, 32) . Similarly, CTL responses can be induced by co-immunization of a T cytotoxic determinant (TCd) and a THd (33±36). THd eliciting T h 1 cytokine pro®les are more ef®cient than those eliciting T h 0 pro®les (30) . As co-immunizations are simple to carry out, it was thought that both strategies offered a convenient way of testing the relative ef®cacy of a large panel of THd to prime both humoral and cytotoxic T cell responses. The results of these experiments are discussed.
Methods

Peptides
Peptides were synthesized by the solid-phase method of Merri®eld (37) using a manual multiple solid-phase peptide synthesizer as described in (38) . At the end of the synthesis, peptides were cleaved, deprotected and washed 6 times with diethyl ether. They were lyophilized and analyzed by HPLC. The purity of peptides was >80% as judged by HPLC. Two well-characterized THd were synthesized: FISEAIIHVLHSR (MYO 106±118 ) corresponding to residues 106±118 from sperm whale MYO (26) and ISQAVHAAHAEINEA (OVA 323±337 ) encompassing residues 323±337 from OVA (27) . Both peptides were used as leading compounds to engineer different types of THd. Peptide MSYSWTGALVTPCAAE (P17), which encompasses residues 2422±2437 from hepatitis C virus NS5 protein and which is not immunogenic per se (39) , was used as a TCd in experiments to induce CTL responses. Peptide hapten NNTRKRIRIQRGPGR (gp120 301±315 ) encompassing residues 301±315 from the principal hypervariable neutralizing domain of HIV type 1 glycoprotein 120 (31) was used in experiments on antibody induction.
Mice
Female BALB/c mice (4±6 weeks old) were purchased from IFFA Credo (Barcelona, Spain). They were hosted in appropriate animal care facilities and handled following institutional guidelines.
Immunization and measurement of cytokine production
Groups of ®ve mice were immunized by s.c. injection at the base of the tail and footpads with 50 nmol peptide emulsi®ed in incomplete Freund's adjuvant (IFA). Ten days later, animals were killed and lymph nodes removed. Lymphocytes were then plated on 96-well plates at 8 Q 10 5 cells/well with culture medium (RPMI 1640 supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 5 Q 10 ±5 M 2-mercaptoethanol) alone or with 30 mM peptide in a ®nal volume of 0.25 ml. Supernatants (50 ml) were removed 24 h later to measure IL-2 production, and 48 h later to measure IFN-g and IL-4. IL-2 was measured using the CTL-L2 bioassay as previously described (30) . IFN-g production was measured by ELISA (PharMingen, San Diego, CA) according to the manufacturer's instructions. IL-4 was measured using the CT4S cell line (kindly provided by Drs W. E. Paul and C. Watson, National Institutes of Health, Bethesda, MD) as described (30) .
Induction and titration of anti-gp120 301±315 antibodies
Groups of ®ve mice were immunized by i.p. injection of 200 ml of a 1:1 emulsion of complete Freund's adjuvant and saline solution containing a mixture of 60 mg (33 nmol) of the peptide hapten gp120 301±315 and 50 nmol THd peptide. A group of mice was bled from the retro-orbital plexus at day 30, and another group was boosted with the same dose of gp120 301±315 and THd peptide in IFA on day 30 and 45, and bled on day 60 after the ®rst injection. Anti-gp120 301±315 antibodies were titrated by ELISA as follows. Microtiter wells (Maxisorp; Nunc, Roskilde, Denmark) were coated with gp120 301±315 by overnight incubation at 4°C with 50 ml peptide solution (20 mg/ml in 0.1 M sodium carbonate buffer). The wells were then washed 3 times with a solution of PBS containing 0.1% Tween 20 (PBST). To block non-speci®c antibody binding, the wells were incubated at room temperature for 1 h with the above buffer, but containing 1% powdered milk (PBSMT). After removing the PBSMT, 50 ml different serum dilutions was added and incubated at 37°C for 1 h. Wells were washed 3 times with PBST and incubated at 37°C for 1 h with a 1/500 solution of goat anti-mouse IgG biotinylated whole antibody (Amersham, Uppsala, Sweden) in PBSMT. After washing 3 times with PBST, the wells were incubated with 1/500 dilution of horseradish peroxidase±streptavidin (Amersham) at 37°C for 1 h, washed 3 times with PBST, and the color reaction started by adding 100 ml of a solution prepared by mixing 10 ml 0.6% acetic acid (pH 4.7), 7.5 ml 33% (w/v) hydrogen peroxide and 100 ml 40 mM water solution of 2,2¢-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma, St Louis MO). Plates were read at 405 nm in a Titertek Multiscan MKII (Flow, dabsystems, Finland) after 1 h.
Immunization and measurement of CTL responses
Groups of two mice were immunized by s.c. injection at the base of the tail and footpads with a mixture of 60 mg (36 nmol) TCd P17 and 0.5, 5 or 50 nmol THd emulsi®ed in IFA. Animals were killed 10 days after immunization and their lymph nodes removed. Cells (8 Q 10 5 /well) were re-stimulated in vitro in 96-well plates using 30 mM THd or 24 mM TCd in 250 ml/well culture medium. CTL activity was estimated by a conventional 51 Cr-release assay (30) and by measuring IFN-g production following stimulation of 48-h cultures with P17 as described above.
Statistical analysis
Correlation between variables was carried out using a Pearson test for parametric samples using the SPSS program version 6.1 for Windows package.
Results
Effect of single amino acid replacements in the sequence of OVA 323±337 and MYO 106±118 on IFN-g and IL-4 production To develop THd peptides eliciting different cytokine pro®les, we selected as leading peptides OVA 323±337 and MYO 106±118 , for which we knew the relative orientation of their residues to the I-A d class II molecule and the TCR (28), and carried out single amino acid substitutions in their sequence. Positions of the modi®ed residues are indicated as P±3 to P13 according to the nomenclature of Scott et al. (28) who aligned both peptides with respect to their interactions with MHC and TCR molecules, P1 being the main anchor residue of both peptides to I-A d molecules. Residues P±1, P5 and P8 point to the TCR in both peptides whereas residues P4 and P9 point to the MHC-II. The orientation of positions P3, P6, P7, P10, P11, P12 and P13 is not clearly de®ned. All these positions were systematically replaced by K, E, M, Y, G and A, representative of different families of amino acids; hydrophilic positively or negatively charged (K and E) hydrophobic, aliphatic or aromatic (M and Y) and small (G and A). This afforded 114 peptides that were used to immunize mice in order to study the capacity of these peptides to prime IFN-g, IL-4 and IL-2 production. Figures 1 and 2 show the results of these experiments for OVA 323±337 -modi®ed and MYO 106±118 -modi®ed peptides respectively. At ®rst glance it is clear that many substitutions in both peptides have a profound effect on cytokine production. In general, OVA 323±337 -modi®ed peptides elicited higher levels of IFN-g and lower levels of IL-2 than MYO 106±118 -modi®ed peptides. In both groups, the most dramatic changes in IFN-g and IL-4 production occurred at positions P±1 and P5, which point to the TCR. These changes do not go hand-in-hand with changes in IL-2 production, . The amino acids of the wild-type peptides are indicated using the single letter code as well as the number they occupy in their corresponding protein sequence. P±3 to P13 are used to designate positions of residues after alignment of OVA 323±337 with MYO 106±118 following the nomenclature given in (28) . P±1, P5 and P8 (and probably P12, see Discussion) are probably the main residues pointing to the TCR, whereas P1 (not studied), P4 and P9 are those pointing to the MHC. The corresponding wild-type peptide is indicated with an asterisk, whereas amino acid replacements are indicated with a letter above each bar. 
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suggesting that modi®cations affect cytokine pro®les rather than cell proliferation. In some cases the levels of IFN-g and IL-4 were more than an order of magnitude higher than the level induced by the parent wild-type peptide. In OVA 323±337 -modi®ed peptides, replacements at positions P±1 and P5 with K, E, M and Y enhanced IFN-g and IL-4 production (with the exception of 328K which only induced IFN-g). Modi®cations with G and A maintained or slightly decreased IFN-g, but increased IL-4 production (with the exception of 328G, which did not induce either of these cytokines). In contrast, modi®-cations in MYO 106±118 at positions P±1 and P5, with K, E, M, Y, G or A, enhanced IFN-g and IL-4 production. Moreover, modi®ed peptides 108G (P±1) and 113A (P5) induced the highest levels of IFN-g in these positions. Amino acid replacements in positions other than P±1 and P5 affected mainly IFN-g production both in OVA 323±337 and MYO 106±118 modi®ed peptides. However, these changes were less important than those observed in P±1 and P5.
T cell help for antibody induction
As discussed earlier in the Introduction, one of the aims of the present study was to develop THd peptides capable of priming T cell help for ef®cient antibody induction. For this purpose we selected a wide range of peptides derived from MYO 106±118 as well as from OVA 323±337 , inducing different ratios of IFN-g and IL-4. Thus, we tested 108G, 108M, 111Y, 112Y, 112G, 113K, 113M and 115M, and also 323K, 329E, 329Y, 330M, 330Y and 336G, as well as wild-type peptides MYO 106±118 and OVA 323±337 with respect to their ability to elicit T h responses for the induction of antibodies against peptide gp120 301±315 . This peptide, from the principal neutralizing domain of HIV type 1 gp120 envelope protein, is not immunogenic per se (31) . Each of the THd peptides was coimmunized with gp120 301±315 as previously described. Antigp120 301±315 antibodies were measured at day 30 and 60 in two different groups of mice. As shown in Table 1 , antigp120 301±315 antibody titers induced with the help of MYO 106±118 -derived peptides were much higher than those induced with OVA 323±337 -derived peptides. Indeed, whereas MYO 106±118 -derived peptides primed antibody induction at day 30, OVA 323±337 -modi®ed peptides did not. Moreover, a difference of over one order of magnitude in the antibody titers against gp120 301±315 was observed at day 60 when using the best peptide from each series: 111Y and 336G respectively. We studied the correlation between IFN-g or IL-4 production by the THd peptides and the anti-gp120 301±315 titers induced. It was found that in the case of MYO 106±118 -derived peptides, both cytokines correlated signi®cantly with anti-gp120 301±315 production at day 30 (R = 0.77, P < 0.05 for IFN-g and R = 0.78, P < 0.05 for IL-4) (Fig. 3A and B respectively) , but no correlation was found at day 60 after three immunizations. In the case of OVA 323±337 -derived peptides, no correlation was found between anti-gp120 301±315 and IFN-g or IL-4 production at day 60. No correlation could be tested at day 30 due to the absence of anti-gp120 301±315 antibodies at this time. A similar test carried out to study the correlation between IFN-g and IL-4 production showed no correlation between both cytokines.
T cell help for CTL induction
To test how different cytokine pro®les affected CTL induction, we used peptides derived from OVA 323±337 , known to be an ef®cient THd for CTL induction (30, 40, 41) . We selected peptides inducing high levels of IFN-g (330M, 331G and 336G), peptides inducing IL-4 and high levels of IFN-g (323K, 327E and 328M), as well as OVA 323±337 to immunize mice at three different doses of THd (0.5, 5 and 50 nmol) in conjunction with 60 mg (36 nmol) of P17, a TCd which is unable to induce a CTL response per se (42). We tested different doses of THd in order to get an insight on how the dose and the cytokine pro®le might affect the ef®cacy of CTL induction. Lymph node cells from all groups of immunized mice were extracted as described in Methods and used to measure CTL activity against P17-pulsed target cells. Since percentages of CTL lysis were found to be too low (data not shown), we decided to measure IFN-g production as an alternative measure of induced CTL activity via the T cell help from THd peptides. It was thought that this was a valid approach because immunization with P17 alone is unable to induce IFN-g production (data not shown). Thus, following in vitro stimulation with the corresponding THd peptide or with the CTL epitope P17 (42), we measured the level of IFN-g production. In three peptides (OVA 323±337 , 323K and 328M) the highest levels of IFN-g induced, both against the THd itself and the TCd, were detected in those animals immunized with the higher dose of THd (50 nmol). By contrast, in peptides 331G, 336G and 330M, the higher levels were detected at the intermediate dose of immunization (5 nmol) (Fig. 4A) . Peptide 327E induced IFN-g against itself, but not against the TCd. As shown in Fig. 4(B) , when the level of IFN-g produced after stimulation with the THd was plotted against the level of IFN-g produced by the TCd peptide P17, a highly signi®cant correlation was found between both parameters (R = 0.842, P < 0.01).
Discussion
Effect of single amino acid replacements in the sequence of OVA 323±337 and MYO 106±118 on IFN-g and IL-4 production Previous work from other groups has shown that single amino acid substitutions in peptides recognized by MHC molecules may alter TCR recognition. Thus, Kersh et al. (43) reported that a substitution of an anchor residue, E73, by D73 in the sequence of THd peptide, although it did not affect binding to I-E k , affected the orientation of the peptide to the TCR molecule, even 10 A Ê away from the substitution. This replacement strongly reduced the T cell response to the peptide presented by the I-E k molecule. Similarly, a single amino acid substitution (Q ® E) in the sequence of a TCd from vesicular stomatitis virus (44) greatly altered the T cell response triggered after recognition of the complex TCd±MHC-I by TCR. Other groups have reported that changes in the sequence of a THd that enhance or decrease binding to MHC-II or TCR molecules may lead to THd inducing T h 1 or T h 2 cytokine patterns respectively (19,21±24) . With the aim of learning rules to modulate the production of IFN-g and IL-4 by Table 1 .
THd, we studied the effect on IFN-g and IL-4 production after replacing residues along the sequence of two well-characterized THd by amino acids from different families: hydrophilic positively or negatively charged (K and E), hydrophobic aliphatic or aromatic (M and Y) and small (G and A). It was hoped that this strategy might lead to the discovery of THd for the ef®cient and specialized induction of humoral or cytotoxic cell responses. As shown in Figs 1(A) and 2(A) , the most pronounced effects on IFN-g and IL-4 production were observed following replacement of residues at positions P±1 and P5, which are reported to point to the TCR (28) both in OVA 323±337 and MYO 106±118 . Since these changes do not go in the same direction as changes in IL-2 production, it is likely that modi®cations affect cytokine pro®les rather than cell proliferation. It could be interpreted that the enhanced IFN-g and IL-4 production at these positions is related to the selection of best-®t TCR from the existing large diversity of the TCR repertoire (45) (Fig. 1) , suggesting a compensation due to the selection of a population of best-®t TCR. From Fig. 1 it is clear that substitutions at P±1 and P5 in OVA 323±337 by amino acids K, E, M and Y afforded peptides inducing higher levels of IFN-g than substitutions by G and A. Interestingly, according to the work of Singh and Thornton (47) , the ®rst group of amino acids has a higher propensity of interaction in proteins than the second group. By contrast, replacement by G or A in MYO 106±118 had an equal or greater effect than K, E, M or Y. We postulate that enhanced IFN-g production following replacements by the small size residues G and A in MYO 106±118 may allow an increased¯exibility of the TCR to interact with the I-A d molecule. This might be related to non-bulky residues A or G not keeping the TCR as far away from the MHC-II as a bulky residue protruding from the I-A d molecule might. This interpretation is in line with the observation that replacement of V by A at position 5 in the sequence of AH1 (a peptide presented by H-2L d ) enhances the stability of the MHC±peptide±TCR complex without altering the binding to H-2L d (48) .
In the present work we show that some replacements at P12 enhanced IFN-g and IL-4 production in OVA 323±337 -modi®ed peptides. This, according to our hypothesis, suggests that P12 is likely to interact with some population of best-®t TCR. By contrast, substitutions at P8, which is described as a position pointing to the TCR, had little or no effect on cytokine production, both in MYO 106±118 and OVA 323±337 , suggesting that P8 might not be that important in TCR recognition. It is interesting to note that, contrary to what was found for substitutions at positions P±1 and P5, which affected both IFN-g and IL-4 production, substitutions in other positions affected mainly IFN-g, with little or no effect on IL-4 production. This is particularly evident for substitutions at L115, which corresponds to P7 in MYO 106±118 . It is tempting to speculate that changes leading to a moderate enhancement in interaction increase IFN-g production, whereas strong changes (like the ones observed for the main positions pointing to the TCR) lead to an enhancement of both IFN-g and IL-4 production. This does not agree with the interpretation by Ise et al. However, since crystallization leads to a single crystal structure of the peptide±MHC complex, and the TCR positions P±1 and P5 assigned by Scott et al. as the main TCR positions coincide with those having the greatest effect on cytokine production in our work, we suggest that anchoring of OVA 323±337 to I-A d may take place in such a way that positions P±1 and P5 are favored to interact with the TCR.
In conclusion, our data suggests that substitutions in the sequence of THd with amino acids having high or a low propensity of interaction in proteins may substantially alter IFN-g and/or IL-4 production. However, in most cases, these changes seem to have greater effect when they correspond to residues pointing to the TCR. This information may be very valuable to engineer peptides eliciting different cytokine pro®les.
T cell help for antibody induction
From Table 1 it is clear that to prime T cell help for antigp120 301±315 antibody induction, MYO 106±118 -derived peptides were much more ef®cient than those derived from OVA 323±337 . The best antibody titers at day 60 were obtained when using THd eliciting both IFN-g and IL-4, i.e. peptides eliciting T h 0 cytokine pro®les. However, THd inducing only IFN-g (112Y, 329E and OVA 323±337 ) were also able to prime T cell help for the induction of anti-gp120 301±315 antibodies. These results indicate that both IFN-g and IL-4 production are relevant in antibody induction. Moreover, among all modi®ed peptides from MYO 106±118 and OVA 323±337 , 323G and 327G were those that induced a cytokine pro®le that was closer to a T h 2 pattern (Fig. 1) . However, none of these two peptides was the best to provide T cell help for the induction of antigp120 301±315 antibodies, even within those peptides derived from OVA 323±337 . This result suggests that a T h 2 pattern is not necessarily the best to induce antibodies. It is not clear to us why MYO 106±118 -derived peptides were much more ef®cient than OVA 323±337 -derived peptides to provide T cell help for antibody induction, especially when considering that peptide 330M that induces similar levels of IFN-g and IL-4 than peptide 111Y leads to greatly different anti-gp120 301±315 antibody titers, 5300 and 242,000 respectively. It could be postulated that cytokines from the T h 1 and T h 2 subsets, other than IFN-g and IL-4, may be of relevance. However, it may also be possible that those steps leading to the presentation of THd by MHC-II may also be of relevance. For instance, the relative ability of THd peptides to enter the APC or bind directly to the MHC-II at the surface of APC. Moreover, since B lymphocytes behave as APC, it may be possible that if the B lymphocytes that recognize the hapten (in our case gp120 301±315 ) simultaneously bind the THd, these lymphocytes might expand more readily via the cytokine stimuli induced in situ after recognition of the THd±MHC-II complex (presented by the B lymphocyte) by the TCR from a HTL, than if the cytokine stimuli is elicited when the THd±MHC-II complex is presented by an APC other than the B lymphocyte itself.
To attempt to interpret the effect of different THd in priming antibody production, we correlated the levels of IFN-g and IL-4 induced by these THd, with anti-gp120 301±315 antibody titers induced at day 60. It was found that neither of these two cytokines correlated signi®cantly with antibody production. Since anti-gp120 301±315 antibody titers at day 60 are obtained following three immunizations (day 0, 30 and 45) with gp120 301±315 and THd, whereas the cytokine pro®les for all THd were obtained after a single immunization with THd, it occurred to us that in correlation studies the antibody titers at day 30 might better re¯ect the T cell help provided by the THd. For this reason, we immunized a new group of mice and measured antibody titers at day 30. When IFN-g and IL-4 production by the group of MYO 106±118 -modi®ed peptides was correlated with antibody production at day 30 ( Fig. 3A and Fig. 3B ), a signi®cant correlation was found for both cytokines (R = 0.77, P < 0.05 for IFN-g and R = 0.78, P < 0.05 for IL-4). These results are in agreement with the published observation that T h 1 and T h 2 CD4 + T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo (52) . No correlation was found between IFN-g and IL-4 primed by THd used in our experiments, suggesting that in our system both cytokines are independent variables. For OVA 323±337 -modi®ed peptides, cytokines could not be correlated with antibody titers at day 30 because these titers were too low or nil. Although we do not have a clear-cut interpretation of why there is a correlation at day 30, but not at day 60, we believe that a possible interpretation might be that changes in cytokine pro®les and concomitant antibody titers may take place after repeated immunizations with THd.
Irrespective of the detailed mechanism by which THd provide help for antibody induction, it is clear that single amino acid replacements in their sequence may have profound effects on their ability to induce antibodies. With respect to MYO 106±118 , some of these peptides have shown an enhanced capacity to provide T cell help for antibody induction, a result that may have useful applications in the production of mAb against non-immunogenic peptides or haptens in general.
T cell help for CTL induction
To study how IFN-g and IL-4 production affected CTL induction, we immunized mice with P17 in combination with different THd peptides derived from OVA 323±337 . We selected OVA 323±337 -derived peptides instead of MYO 106±118 -derived peptides because we had shown that OVA 323±337 is more ef®cient than MYO 106±118 in priming T cell help for CTL induction (30) . We selected peptides inducing high levels of IFN-g, but different IFN-g:IL-4 ratios (Fig. 1A) . As shown in Fig. 4 , peptides having a strong T h 1 character (331G, 336G and 330M) induced the strongest CTL response at the intermediate dose of immunization (5 nmol), whereas the wild-type peptide OVA 323±337 which elicits a weaker T h 1 cytokine response pattern, and peptides 323K and 328M, which produce high levels of IFN-g, but also IL-4 (T h 0 cytokine pattern), were more active at 50 nmol. Peptide 327E, which also elicited a T h 0 cytokine pro®le, provided very little help to the P17 peptide at the three concentrations tested. When the levels of IFN-g induced by each THd peptide were correlated with the corresponding level of IFN-g induced by P17, a high correlation (P < 0.01) was observed.
In conclusion, the strongest CTL inductions were obtained after immunization with a TCd and a THd eliciting T h 1 cytokine pro®les (Fig. 4) . The dose of THd peptide was also found to be of great relevance for ef®cient CTL induction. This last result is in agreement with that reported by Alexander et al. (53) where a dose of 5 nmol THd PADRE was more ef®cient than 100 nmol to prime T cell help for CTL induction. These ®ndings have obvious implications when developing vaccination protocols. As previously reported by us (30, 33, 41) , exogenous THd peptides may prove to be very valuable to induce CTL responses in cancer, as well as in viral chronic infections. Finally, although more speculative, the in¯uence of amino acid residues pointing to the TCR may be of value in predicting immunodominant THd from antigens. Similar reasoning might obviously be applied in the understanding of the immunogenicity of peptides presented by MHC-I. 9672673897). N. C. was a recipient of a scholarship from Gobierno Vasco. 
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